The guidelines of the American Diabetes Association (ADA) for diagnosis of diabetes have a global impact. The use of point-of-care (POC) assays for haemoglobin A1c (HbA1c) in the diagnosis of diabetes is not recommended in these guidelines on the grounds that the devices are not sufficiently accurate for the diagnosis of diabetes. 1 However, the same guidelines cite evidence that two of eight POC instruments meet the generally accepted analytical performance criteria, 2 and a recent update (by the same authors) reported that four of seven meet the same performance criteria. 3 These are Afinion, DCA Vantage, B-analyst and Cobas B101. They all passed the National Glycohemoglobin Standardisation Program criteria (total CV 4 3.1% in SI units and 42.1% in Diabetes Control and Complications Trial (DCCT) units). Most of the more frequently occurring haemoglobin (Hb) variants have not been reported to interfere with HbA1c measurement on these instruments with the exception of HbAE on the Cobas B101. 3 The ADA guidelines for HbA1c measurement recommend an intralaboratory CV of <2% and an interlaboratory CV of <3.5%. For a single method, the goal should be an interlaboratory CV <3%. 1 Participation in an external quality assurance scheme is mandatory for every laboratory and POC instrument. An editorial in Clinical Chemistry on the performance of HbA1c assay methods noted that some POC methods perform well in laboratories as evidenced by College of American Pathologists GH-2 proficiency surveys. 4 Recommending that POC machines should not be used to measure HbA1c in the diagnosis of diabetes, but can be used to monitor patients with diabetes, is illogical. In order to maintain guideline credibility, consideration should be given to amending the recommendations on the use of POC instruments for HbA1c measurement, to reflect technical performance improvements when units have been shown to perform to the recommended standards. Obligatory participation in standard quality assurance programmes must be included. In the US, this will require a reversal of the Clinical Laboratory Improvement Amendments (CLIA)-waived status for HbA1c POC, which will legally oblige POC users to participate in external quality control schemes. 5 
